Allison Bratzel
Stock Analyst at Piper Sandler
(4.47)
# 363
Out of 5,182 analysts
61
Total ratings
63.27%
Success rate
18.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Overweight | $26 → $30 | $9.13 | +228.59% | 3 | Apr 22, 2026 | |
| HUMA Humacyte | Maintains: Neutral | $3 → $1 | $0.81 | +24.08% | 3 | Mar 30, 2026 | |
| TYRA Tyra Biosciences | Maintains: Overweight | $42 → $56 | $36.92 | +51.68% | 3 | Mar 20, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $51 → $58 | $46.29 | +25.30% | 5 | Mar 4, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $87 → $100 | $72.23 | +38.45% | 5 | Feb 27, 2026 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $35 → $38 | $40.81 | -6.89% | 4 | Feb 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $84 | $53.81 | +56.12% | 1 | Feb 6, 2026 | |
| INCY Incyte | Maintains: Overweight | $102 → $110 | $95.72 | +14.92% | 4 | Feb 6, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $6 → $4 | $1.42 | +181.69% | 2 | Feb 6, 2026 | |
| REPL Replimune Group | Maintains: Overweight | $13 → $14 | $2.68 | +422.39% | 3 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.59 | +151.57% | 1 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $820 → $930 | $783.74 | +18.66% | 15 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $112 | $111.90 | +0.09% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $23.99 | +379.37% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $7.20 | +261.11% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $30.51 | -24.61% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $27.85 | -21.01% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $7.50 | +166.67% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $4.16 | +380.77% | 1 | Oct 13, 2023 |
MeiraGTx Holdings
Apr 22, 2026
Maintains: Overweight
Price Target: $26 → $30
Current: $9.13
Upside: +228.59%
Humacyte
Mar 30, 2026
Maintains: Neutral
Price Target: $3 → $1
Current: $0.81
Upside: +24.08%
Tyra Biosciences
Mar 20, 2026
Maintains: Overweight
Price Target: $42 → $56
Current: $36.92
Upside: +51.68%
Scholar Rock Holding
Mar 4, 2026
Maintains: Overweight
Price Target: $51 → $58
Current: $46.29
Upside: +25.30%
Ionis Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $87 → $100
Current: $72.23
Upside: +38.45%
Travere Therapeutics
Feb 6, 2026
Maintains: Neutral
Price Target: $35 → $38
Current: $40.81
Upside: -6.89%
BioMarin Pharmaceutical
Feb 6, 2026
Maintains: Overweight
Price Target: $122 → $84
Current: $53.81
Upside: +56.12%
Incyte
Feb 6, 2026
Maintains: Overweight
Price Target: $102 → $110
Current: $95.72
Upside: +14.92%
Akebia Therapeutics
Feb 6, 2026
Maintains: Overweight
Price Target: $6 → $4
Current: $1.42
Upside: +181.69%
Replimune Group
Feb 5, 2026
Maintains: Overweight
Price Target: $13 → $14
Current: $2.68
Upside: +422.39%
Feb 5, 2026
Maintains: Overweight
Price Target: $3 → $4
Current: $1.59
Upside: +151.57%
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $783.74
Upside: +18.66%
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $111.90
Upside: +0.09%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $23.99
Upside: +379.37%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $7.20
Upside: +261.11%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $30.51
Upside: -24.61%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $27.85
Upside: -21.01%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $7.50
Upside: +166.67%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $4.16
Upside: +380.77%